The present study was carried out to assess the effects of protease inhibitor (PI) therapy on basal whole body protein metabolism and its response to acute amino acid-glucose infusion in 14 human immunodeficiency virus (HIV)-infected patients. Patients treated with PIs (PIϩ, 7 patients) or without PIs (PIϪ, 7 patients) were studied after an overnight fast during a 180-min basal period followed by a 140-min period of amino acid-glucose infusion. Protein metabolism was investigated by a primed constant infusion of L-[1-
THE INTRODUCTION OF PROTEASE INHIBITORS (PIs) is a landmark event in the history of HIV disease treatment and has greatly improved the survival and quality of life of patients. However, patients with HIV diseases under PI therapy for long periods of time frequently develop lipid and glucose metabolism alterations such as lipodystrophy, including peripheral lipoatrophy and increased visceral fat, hyperlipidemia (i.e., elevated plasma triglycerides and cholesterol), diabetes mellitus, insulin resistance, and cardiovascular diseases (19, 32, 37) .
Moreover, muscle wasting remains a significant clinical problem in patients with acquired immune deficiency syndrome (AIDS), even under PI therapy (15, 38) . AIDS is characterized by a predominant loss of lean body tissue (22) , which is considered as a major predictor of morbidity and mortality (20, 21) . Multiple factors in different combinations contribute to lean body mass loss, including reduced food intake, nutrient malabsorption, and abnormal utilization and excretion of nutrients. In addition, elevated resting energy expenditure and specific disturbances in protein turnover might be responsible for decreased lean body mass. An increased whole body protein turnover has been reported in the postabsorptive state in HIV-infected patients compared with healthy control subjects (11, 17, 26, 48) . In contrast, a decrease in whole body protein turnover has been observed in the fed state in some (31, 40) but not all studies (26, 39) , which suggests that there is an altered response to food intake.
Contrasting with glucose and lipid metabolism, there is no information available on the effect of PI therapy on protein metabolism in HIV-infected patients. A better understanding of the regulation of protein metabolism in HIV-infected patients is needed to prevent losses of lean body mass and to establish dietary protein requirements. This study has been therefore initiated to investigate the effects of PI therapy on whole body protein turnover in HIV-infected patients. For this purpose, we compared whole body leucine kinetics in two groups of HIVinfected patients treated with (PIϩ) or without (PIϪ) PIs. The patients were studied 1) in the postabsorptive state to determine the effect of PI therapy on the basal whole body leucine metabolism and 2) during an acute intravenous amino acidglucose infusion to evaluate a possible effect of PI treatment on the response of whole body metabolism to an anabolic state.
MATERIALS AND METHODS
Patients. The protocol was approved by the local ethics committee (Comité Consultatif pour la Protection des Personnes en Recherche Biomédicale pour la Région Auvergne). Each patient provided written informed consent before enrollment. The study population consisted of 14 male patients recruited from the Department of Infectious Diseases at the University Hospital in Clermont-Ferrand, France. On the basis of the ELISA and Western blot assays, all were HIV seropositive. History of clinical events was recorded for all patients, and a physical examination was performed at the time of the study.
Only patients who had been free of any opportunistic infection and persisting fever for a period Ն 6 mo before enrollment were included. Patients with diarrhea or loss of appetite were excluded. No patient had ever been given any testosterone derivatives or human growth hormone.
Two groups of patients were selected on the basis of their therapy: patients treated with a combination therapy of three agents, including at least one PI (patients treated with PIs, PIϩ group; n ϭ 7) and patients under an antiretroviral regimen that did not include PIs (patients treated without PIs, PIϪ group; n ϭ 7). PIϪ patients were treated with a combination of nucleosidic reverse transcriptase inhibitors (NRTIs) and/or nonnucleosidic reverse transcriptase inhibitor (NNRTI; Table 1 ). Each group exhibited the same known duration of HIV infection (7 Ϯ 2 yr in PIϪ and 7 Ϯ 1 yr in PIϩ group) and antiretroviral treatments (4.1 Ϯ 1.4 yr in PIϪ and 3.6 Ϯ 0.6 yr in PIϩ group). Patients underwent the present therapy for 1.6 yr (0.5 yr minimum, 3 yr maximum) in the PIϪ group and 1.9 yr (1 yr minimum, 2.5 yr maximum) in the PIϩ group. PIs were prescribed when the previous combination therapy failed, i.e., when plasma virus load increased significantly (Ͼ0.5 log 10 copies/ml) and CD4 number decreased (nadir CD4 were 342 Ϯ 36 and 90 Ϯ 41 CD4 cell count/mm 3 , respectively, in PIϪ and PIϩ groups; means Ϯ SE, P Ͻ 0.001). This could explain why the CD4 cell counts tend to be lower (P ϭ 0.07) in the PIϩ group than in the PIϪ group, although the viral loads did not differ between groups (Table 1) . Weight history was available for all patients. Before initiation of the present therapy (i.e., from the first diagnosis to beginning the present therapy), only one subject had Ͼ10% weight loss (in PIϩ group), two had Ͼ5% weight loss (1 in each group), four had Ͻ5% weight loss (1 in PIϩ group and 3 in PIϪ group), and seven had gained weight (0.9 -13%). PI therapy resulted in a body weight gain (65.7 Ϯ 1.9 vs. 69.8 Ϯ 1.7 kg before and after PI therapy; means Ϯ SE, P Ͻ 0.05 by paired t-test). Indeed, only one patient lost weight (Ϫ1.5%), whereas the other subjects gained weight (2.1-6.1%) in the PIϩ group. In the PIϪ group, the present therapy did not change mean body weight (74.5 Ϯ 6.3 vs. 72.7 Ϯ 5.3 kg before and after the present therapy period; not significant by paired t-test); one patient had Ͼ10% weight loss, two had Ͻ5% weight loss, and four gained weight (0.7-4.7%).
Dietary control. Each volunteer was given a questionnaire, with a dietitian assigned to define the volunteer's usual dietary intake. Diet survey analyses of usual intake indicated that the subjects in the two groups consumed similar and adequate amounts of protein, carbohydrate, and fat before the study ( 8 .56. A beet-derived glucose solution (100 g/l, with a low natural abundance of 13 C) was obtained from Braun (St. Gallen, Germany). It was verified in preliminary experiments that the natural abundance in glucose and amino acids infused in conjunction with insulin had no effect on basal 13 C enrichments in plasma leucine and expired CO2. This suggests that the compounds infused did not artifactually modify 13 Sampling. Arterialized blood (obtained by placing the forearm and hand in a heating box at 60°C) was taken from the dorsal hand catheter at Ϫ30 and Ϫ10 min before the basal period, at 130, 150, and 170 min during the basal period and at 260, 280, 300, and 320 min during amino acid-glucose infusions (i.e., 80, 100, 120, and 140 min after beginning amino acid-glucose infusion; Fig. 1 ). Blood samples were collected in heparinized tubes and centrifuged at 4°C, and the resulting plasma was stored at Ϫ20°C for subsequent analyses. Breath samples were collected during 4-min periods at the last three sampling points during the basal period and the last four sampling points during the amino acid-glucose infusion. The expired breath was dried on CaCl 2 and passed through a gasometer (Slonic, Schlumberger, France) for volume determination. A fraction of the expired-air sample was drawn into a bottle filled with a soda lime-sodium hydroxide mixture (1:4 wt/wt) to measure the CO 2 content. Another fraction was collected into evacuated glass tubes (Vacutainer; BectonDickinson, Grenoble, France) for storage before 13 C enrichment analysis. The rate of expired CO2 tended to be less in PIϩ group during the basal period (8.3 Ϯ 1.4 and 11.5 Ϯ 0.9 mmol/min in groups PIϩ and PIϪ, respectively, P ϭ 0.08; each individual value was the mean of 3 measurements). It was not modified by amino acid-glucose infusion (9.0 Ϯ 1.8 and 11.5 Ϯ 0.5 mmol/min, P ϭ 0.2; means of 4 measurements).
Analysis of 13 C enrichment. Plasma L-[1-13 C]leucine and [ 13 C]␣-ketoisocaproic acid (KIC) enrichments were determined by GC-MS. Leucine was extracted with chloroform-acetone and KIC with dichloromethane acid (10) . Tert-butyldimethylsilyl derivatives of leucine and KIC were prepared from plasma extracts, as described previously (10) , and analyzed by GC-electron impact mass spectrometry (mass selective detector 5972, coupled with a gas chromatograph 5890 series II; Hewlett Packard, Les Ullis, France), and the ions were monitored with mass-to-charge ratio 302, 303 ([ 13 C]leucine). Breath 13 CO2 enrichments were measured directly by isotopic ratio mass spectrometry, using a VG Isochrom (Micromass HK, Manchester, UK).
Assays. The concentrations of free plasma amino acids were measured by ion exchange chromatography. A special protein precipitation protocol was developed to avoid sample dilution. Two hundred fifty microliters of a sulfosalicylic acid solution (0.916 mol/l dissolved in ethanol with 0.533 mol/l thiodiglycol and 1.040 mmol/l norleucine) were added to tubes and evaporated to dryness. One milliliter of plasma was then added to tubes and incubated on ice for 1 h. The samples were then centrifuged for 1 h (3,500 g, 4°C), and 500 l of supernatant were added to 250 l of 0.1 M lithium acetate buffer, pH 2.2. Amino acid concentration was determined using an automated amino acid analyzer (Biotronic LC 3000, with BTC 2410 resin; Roucaire, Velizy, France). Plasma tryptophan was determined using a fluorometric method (5) and an LS30 (PerkinElmer, Buckinghamshire, UK).
Plasma substrates were determined on an automatic analyzer (Chem 1; Bayer Diagnostics, Puteaux, France), using enzymes (hexokinase and glucose-6-phosphate dehydrogenase for glucose; urease and glutamate dehydrogenase for urea; cholesterol esterase, cholesterol oxidase, and peroxidase for cholesterol; lipase, glycerokinase, pyruvate kinase, and lactate dehydrogenase for triglycerides).
Retinol-binding protein, ␣1-acid glycoprotein, C-reactive protein, and fibrinogen were measured by immunonephelometry, using routine hospital assays. Plasma insulin and total plasma testosterone levels were determined by chemiluminescent immunoassay, using commercial kits (Immulite; Diagnostic Products, Los Angeles, CA).
Calculations. Whole body leucine kinetics were calculated using samples taken during the last hour of the basal (at 130, 150, and 180 min) and infused periods (at 260, 280, 300, and 320 min). After checking of the isotopic steady state for the last hour of each period (see below), mean plateau enrichment values were used to calculate leucine kinetics.
Total whole body leucine turnover rate (Q, mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was determined using the equation (28, 25, 41, 43, 44 )
where F is the L-[1- 
where 13 CO2 production (mol/min) ϭ V CO2 (mol of CO2/min) ϫ IECO2 ϫ 1/R, IECO2 (molar percent excess) is the expired 13 CO2 enrichment, and R (80%) is a factor correcting for incomplete recovery of labeled bicarbonate (1) . IEa represents either the plasma L-[1- 13 C]leucine or the plasma [ 13 C]KIC enrichments. Because oxidative leucine disposal rate is a function of the rate of 13 CO2 production, which is the product of the volume of CO2 expired ϫ 13 C enrichment of expired CO2, we checked that this product reached a steady state during the basal and infused periods by testing for the absence of a significant slope when analyzed with linear regression. Originally, we had nine patients in the PIϩ group, but unfortunately the determination of this isotopic steady state led us to exclude two subjects because their 13 CO2 production did not reach a steady state during [
13 C]leucine infusion. According to the model, the following equation applies:
where F is the L-[1-13 C]leucine infusion rate, I is the rate of intravenous unlabeled leucine infusion (I ϭ 0 in the basal period), Ra is the endogenous leucine appearance rate (an index of protein breakdown), and R d is the nonoxidative leucine disposal rate (an index of protein synthesis) from plasma (all in mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Knowing Q, F, I, and Ox: and Net leucine balance, an index of protein deposition, is calculated as Rd Ϫ Ra. The whole body leucine kinetics rates were expressed per kilogram of fat-free mass (mol ⅐ kg FFM Ϫ1 ⅐ min Ϫ1 ) because the PIϩ group had lower FFM than the PIϪ group.
Statistical analysis. All data are expressed as means Ϯ SE. Paired t-tests were used to compare data obtained during the basal and the amino acid-glucose infusion periods. A two-way ANOVA (main effect therapy of patients and amino acid-glucose infusion) and an unpaired Student's t-test were also used to compare the results in PIϩ and PIϪ groups. P Ͻ 0.05 was considered to be significant.
RESULTS
Characteristics of the patients. The two groups did not differ with respect to age, height, body weight, and body mass index (Tables 1 and 2 ). The dual-energy X-ray absorptiometry (Table  2 ) (37) showed that FFM tended to be lower in the PIϩ than in the PIϪ group (P ϭ 0.07). It became significant when expressed in percentage of total body weight. The body fat mass (BFM) was therefore higher in the PIϩ than in the PIϪ group (P ϭ 0.06 when expressed in kg, P ϭ 0.005 when expressed in %total body wt). As is shown in Table 2 , the distribution of BFM clearly differed between groups. There was an accumulation of abdominal BFM in the PIϩ group (57.3 Ϯ 1.4 vs. 42.9 Ϯ 2.1% of total BFM in the PIϩ group and PIϪ group, respectively; P Ͻ 0.05) associated with a loss of BFM in the arms (9.7 Ϯ 0.4 vs. 11.7 Ϯ 0.5% of total BFM in the PIϩ group and PIϪ group, respectively; P Ͻ 0.05) and legs (26.9 Ϯ 1.4 vs. 35.5 Ϯ 2.1% of total BFM in the PIϩ group and PIϪ group, respectively; P Ͻ 0.05). PIϩ patients had a significantly higher trunk-to-appendicular fat mass ratio than PIϪ subjects (Table 2) , which confirmed trunk adiposity in the PIϩ group. A ratio of trunk-to-appendicular fat tissue equaling 1.1 was used to identify subjects with trunk adiposity at baseline (42) . All seven of the PIϩ patients presented a trunk-to-appendicular fat mass ratio Ͼ1.1 (1.23-1.95), whereas only one PIϪ patient had such an elevated value (0.63-1.31).
Total plasma testosterone levels were not significantly different between the two groups (Table 3) . Plasma protein contents, indicators of the nutritional state (albumin, prealbumin, retinol-binding protein) and/or the inflammatory state (␣1-acid glycoprotein, fibrinogen, and C-reactive protein), were also normal and did not differ between the two groups. Plasma cholesterol was normal and did not differ between the two groups. By contrast, triglycerides were higher in the PIϩ than in the PIϪ group (P Ͻ 0.05). Basal plasma insulin and glucose concentrations were not significantly different between the two groups (Table 3) . Amino acid-glucose infusion increased plasma insulin in both groups (P Ͻ 0.05 vs. basal values). This increase tended to be more pronounced in PIϩ patients (18.4 Ϯ 2.3 and 11.2 Ϯ 2.6 mUI/l in the PIϩ group and PIϪ group, respectively; P ϭ 0.06). Plasma glucose also significantly increased during amino acid-glucose infusion (5.3 Ϯ 0.3 and 5.4 Ϯ 0.2 mmol/l in PIϩ group and PIϪ group, respectively) but remained similar in both groups.
Plasma essential free amino acid concentrations were similar in the PIϩ and PIϪ groups during the basal period (Table 4) , except for histidine, which was significantly higher in the PIϩ than in the PIϪ group. Amino acid-glucose infusion significantly increased most essential plasma amino acids in both groups, except for threonine, which was not significantly increased in the PIϪ group. Most amino acids reached similar levels under infusion in the PIϩ and PIϪ groups, except for histidine, which was increased at higher levels in the PIϩ (Fig. 2) during the final hour of basal (i.e., 130 -180 min) and infused (260 -320 min) periods. The mean coefficients of variation for plasma 13 C leucine enrichments were 4.4 and 6.1% during the basal period and 6.6 and 5.2% during the infused period in the PIϪ group and PIϩ group, respectively. It was 4.1 and 3.6% during the basal period and 3.8 and 3.3% during the infused period in the PIϪ group and PIϩ group, respectively, for plasma [ 13 C]KIC enrichments. At the basal state, 13 CO 2 production, plasma [ 13 C]leucine, and plasma [
13 C]KIC enrichments were not significantly different between the two groups. Amino acid-glucose infusion significantly increased 13 CO 2 production in both groups (P Ͻ 0.05), but to a greater extent in the PIϪ than in the PIϩ group ( Fig. 2A) . Conversely, plasma [ 13 C]leucine enrichments decreased under amino acid-glucose infusion in the two groups (Fig. 2B ), but this decrease was more pronounced in the PIϩ than in the PIϪ group (P ϭ 0.0003 in the PIϩ group vs. P ϭ 0.03 in the PIϪ group, respectively). Plasma [
13 C]KIC enrichments significantly decreased under amino acid-glucose infusion in the PIϩ group (Fig. 2C) .
Basal leucine kinetics. During the basal period, PI therapy did not significantly change the total leucine flux (2.37 Ϯ 0.12 and 2.18 Ϯ 0.13 mol⅐kg FFM Ϫ1 ⅐min Ϫ1 in the PIϪ group and PIϩ group, respectively). Similarly, endogenous leucine appearance (an index of protein breakdown), nonoxidative leucine disposal (an index of protein synthesis), and oxidative leucine disposal did not differ significantly between groups during the basal period with the use of either plasma [ 13 C]leucine (Fig. 3) or [ 13 C]KIC enrichments (not shown). Basal leucine balance (Fig. 4) Ϫ1 in the PIϪ group and PIϩ group, respectively; P Ͻ 0.05 vs. basal period). By contrast, amino acid-glucose infusion significantly decreased the endogenous leucine appearance (Fig. 3A) . Amino acid-glucose infusion significantly increased (P Ͻ 0.05) the oxidative leucine disposal in both groups, with the use use of either plasma [
13 C]leucine (Fig. 3B [ 13 C]KIC in the basal period and infused period, respectively; P ϭ 0.1; Fig. 3C ). As was expected, the net leucine balance showed a switch from negative to positive values by amino acid-glucose infusion in both groups (Fig. 4) . However, it became significantly more positive in patients treated with PIs than in patients treated without PIs (Ϫ0.074 Ϯ 0.040 to 0.501 Ϯ 0.099 mol⅐kg FFM Ϫ1 ⅐min Ϫ1 during the basal period and infused period, respectively, in the PIϩ group vs. Ϫ0.186 Ϯ 0.032 to 0.181 Ϯ 0.062 mol⅐kg FFM Ϫ1 ⅐min Ϫ1 in the PIϪ group). The incremental increase in leucine balance (infused values Ϫ basal values) was higher in PIϩ than in PIϪ patients (0.575 Ϯ 0.064 and 0.367 Ϯ 0.071 mol⅐kg FFM Ϫ1 ⅐min Ϫ1 in the PIϩ group and PIϪ group, respectively, P ϭ 0.05). These same relative changes were observed by using the plasma [
13 C]KIC to represent the precursor pool enrichment (data not shown).
DISCUSSION
Although the introduction of PI treatment in HIV-infected patients has resulted in a pronounced decline in HIV-related morbidity and mortality, it is well recognized that PI therapy is associated with a variety of side effects, including lipid and carbohydrate metabolism disorders. Indeed, lipodystrophy has largely been described in HIV-infected patients receiving PIs (3, 7, 19, 46) . Although the loss of lean body mass is still a major problem for patients treated with PIs, protein metabolism has been poorly studied. To our knowledge, the present study is the first to investigate the whole body protein metabolism in HIV-infected patients treated with or without PIs during postabsorptive conditions and during an amino acidglucose infusion.
Despite a limited cross-sectional study, it appears that protease inhibitor-containing regimens may favor whole body protein anabolism in HIV-infected patients.
The improvement in leucine balance during the basal period is indicative of a positive effect of PI treatment on whole body protein anabolism, which suggests a possible limitation of the usual loss of body proteins during the postabsorptive state. Accordingly, a decrease in protein catabolism has recently been reported in fasted HIV-infected prepubertal children receiving PIs (16) . Measurements of whole body protein turnover during the amino acid-glucose infusion further suggested this beneficial effect. Indeed, the net leucine balance was clearly higher in PI-treated than in non-PI-treated patients during amino acid-glucose infusion. This marked improvement in the leucine balance with PI treatment was due mainly to an increase in nonoxidative leucine disposal (i.e., protein synthesis) (13-14% vs. basal, P Ͻ 0.05 in the PIϩ group; Ϫ10 -11% vs. basal, not significant in the PIϪ group).
However, measurements of body composition did not show any increase, but rather a decrease, in body FFM (an index of muscle mass) in PI-treated patients. This means that the effect of PIs on protein metabolism affected organs other than skeletal muscle, e.g., the liver and splanchnic area. It has been shown (30) that intravenous amino acid infusion is able to stimulate protein synthesis in the splanchnic bed of healthy subjects. We might hypothesize that it was also the case in HIV-infected patients. The fact that patients with PIs had a lower FFM than patients without PIs supports the notion that amino acids were utilized to a lesser extent in muscle and were consequently more available in the liver of patients receiving PIs. A specific stimulation of liver protein synthesis in patients treated with PIs is therefore conceivable. Unfortunately, measurements of whole body turnover rate, using the [ 13 C]leucine constant infusion method, reflect amino acid metabolism in all proteins of the body and did not allow to discriminate either muscle or liver protein metabolism. An increase in whole body protein synthesis, along with a decrease in muscle mass, has already been reported in AIDS-wasting patients compared with HIV seronegative subjects (48) . More recently, the same group reported that reducing plasma HIV RNA improved muscle protein synthesis without increasing muscle mass (47) . The failure to restore muscle mass in PI-treated patients, despite the fact that whole body protein synthesis was increased, suggests that muscle protein synthesis could contribute less to the elevated rate of whole body protein synthesis.
Alternatively, this discrepancy allows for other explanations. First, our findings are limited by the fact that we did not know the FFM of the patients before they started their present therapy. Second, the anabolic response observed in the present study was obtained by parenteral "feeding," which avoids the confounding effects of malabsorption presently found in HIVinfected patients, which suggests a best availability of substrates for protein synthesis. Third, the improvement in whole body protein synthesis observed in PI-treated patients occurred during the infusion of a balanced amino acid-glucose mixture (protein synthesis being similar in both groups at the basal state), which suggests that PI therapy should be beneficial in feeding conditions only under adequate amino acid supply. Last, a short-term positive result might not indicate long-term beneficial effects on protein deposition. A modest but significant increase (3%) in lean body mass has been observed (4) after a 12-wk period of nutritional supplements combined with dietary counseling in HIV-infected patients.
During the intravenous amino acid-glucose infusion, the total whole body leucine flux increased in HIV-infected patients (10%, P Ͻ 0.05; and 24%, P Ͻ 0.0001 in PIϪ and PIϩ patients vs. the basal period). This observation is in agreement with previous data (26) , which showed respective increases of 27 and 16% in the whole body leucine flux during an administration of intravenous nutrition in stages II and IV of HIVinfected subjects compared with the fasted state. Those authors also showed that HIV infection did not quantitatively impair the acute anabolic response to intravenous nutrition compared with control subjects. The present study does not allow for suggesting the same conclusion, because healthy subjects were not included. However, in a previous study, we showed that a similar amino acid-glucose infusion, albeit in the presence of insulin, did not stimulate the nonoxidative leucine disposal in healthy subjects. As was observed in the PIϪ group in the present study, amino acid-glucose infusion also impaired nonoxidative leucine disposal (Ϫ10%) (41) . Moreover, Giordano et al. (14) clearly showed that amino acid infusion, which increased plasma amino acids by 1.25-1.50 above baseline (as in the present study), did not change nonoxidative leucine disposal in healthy volunteers. Therefore, we can hypothesize that the improvement of whole body protein synthesis by amino acid-glucose infusion might be specific to the PI therapy.
The increase in protein synthesis during amino acid-glucose infusion occurred along with a lower leucine oxidation in patients treated with PIs (Ϫ28%), using either plasma [ 13 C]leucine or [ 13 C]KIC enrichements. These findings support the hypothesis that PI treatment may reduce the amino acid oxidation pathway to spare amino acids for whole body protein synthesis. Leucine concentration in intracellular precursor pools of protein synthesis or leucine degradation may increase differentially in PIϩ and PIϪ patients after infusion. Unfortunately, the leucine transport into these pools was not available.
Alternatively, a selective defect in leucine degradation might be considered, due to the fact that adipose tissue contributes to the degradation of leucine. The KIC is decarboxylated by branched-chain keto acid dehydrogenase (EC 1.2.4.4) to form isovaleryl CoA, which is further oxidized through reactions similar to those by which fatty acyl-CoA is degraded. We might speculate that the PI-induced abnormalities of adipose tissue altered these reactions as well as lipid metabolism (8, 45) . Another specific mechanism is that leucine transamination for the synthesis of glutamine may be inhibited. Yarasheski et al. (47) demonstrated that highly active antiretroviral therapy decreased glutamine synthesis. Because PI treatment has been shown to decrease energy expenditure (33), a nonspecific reduction of substrate catabolism could not be excluded. Accordingly, CO 2 production was reduced in PIϩ compared with PIϪ patients.
Amino acid-glucose infusion increased plasma amino acids concentrations in both groups. The mean incremental increase (i.e., infused values Ϫ basal values) in essential plasma free amino acids was not significantly different between the two groups despite a trend toward a greater effect in the PIϩ than in the PIϪ group (53 Ϯ 8 vs. 35 Ϯ 4% of basal values, P ϭ 0.08). When considering individual amino acids, it appears that the incremental increase in plasma leucine and isoleucine during amino acid-glucose infusion was greater in PIϩ than in PIϪ patients. This is consistent with an inhibition of the degradation of these branched-chain amino acids in PIϩ patients. Moreover, branched-chain amino acids have been shown to stimulate protein synthesis (13, 29) , and this might partly explain the stimulation of protein synthesis in PIϩ group. It also appears that the incremental increase in threonine was not significant in patients treated without PIs (15%), whereas it was significant in patients treated with PIs (20%; P Ͻ 0.05). The incremental increase in methionine was also smaller in the PIϪ (32%) than in the PIϩ (61%) group (P Ͻ 0.05). We can thus hypothesize that these amino acids were less rate limiting for protein synthesis in the PIϩ than in the PIϪ group. Indeed, in a previous experiment (23), we demonstrated that threonine and possibly methionine might be rate limiting for whole body protein synthesis in HIV-infected patients compared with healthy subjects. Thus these findings suggest that PI therapy decreases the limiting aspect of some amino acids in HIV-infected patients, favoring whole body protein anabolism.
An increase in whole body protein anabolism could be surprising in HIV-infected patients treated with combination regimens, including PIs, because it is recognized that PI-based therapy is associated with a number of metabolic complications, including insulin resistance (19) . Insulin sensitivity of patients was not investigated in the present study. In the basal state, some indirect indicators such as fasting plasma insulin and glucose (Table 3) , as well as plasma insulin-glucose ratio (1.52 Ϯ 0.30 vs. 1.40 Ϯ 0.49 in PIϩ and PIϪ groups, not significant), did not support an insulin resistance state in either group. However, at the end of amino acid-glucose infusion, plasma insulin tended to be higher in the PIϩ than in the PIϪ group (Table 3) , and the insulin-glucose ratio was significantly increased in PI-treated patients (3.45 Ϯ 0.32 vs. 1.99 Ϯ 0.38 in the PIϩ group and PIϪ group, respectively; P Ͻ 0.05). Taken together, these data may suggest a decrease in insulin sensitivity in PI-treated patients. Such a decrease would not be compatible with the increase in whole body protein synthesis obtained in PIϩ patients. However, previous studies (19, 32, 38) that describe insulin resistance as a consequence of PI treatment generally concerned glucose and lipid metabolisms. Indeed, a link between peripheral lipid storage and insulin sensitivity has been suggested (6) . Therefore, the increase in whole body protein synthesis and leucine balance observed in PIϩ compared with PIϪ patients resulted presumably from insulin-independent mechanisms. Accordingly, the dose-response curves for protein synthesis as a function of plasma insulin showed that the maximum insulin effect was obtained at very low insulin levels (12) , and an additional increase in plasma insulin did not further increase protein synthesis. In other words, insulin appears to be a rather permissive modulator for protein synthesis (34, 36) .
Our data suggest that highly active antiretroviral therapy, including PIs in HIV-infected patients, might favor whole body protein anabolism compared with antiretroviral therapy without PIs. The mechanisms involved in such an effect are not clear. Indeed, a recent report (18) showed that PIs, and especially indinavir, impaired protein synthesis in mouse C 2 C 12 myocytes. Whether these changes occur in vivo remains to be determined. Alternatively, NRTIs are known to induce mitochondrial toxicity, which subsequently leads to mitochondrial DNA depletion and dysfunction of the respiratory chain (i.e., decreased ATP synthesis). We can hypothesize that such alterations might influence protein metabolism because both protein synthesis and degradation require ATP. Moreover, it has been shown that NRTI toxicity is associated with hyperlactatemia and lactic acidosis (25, 27) , which could alter protein metabolism. Acute or chronic acidosis has been shown to increase whole body proteolysis and decrease protein balance (2, 9) . Although all patients received NRTIs (Table 1) , the toxic effects of NRTIs might be more pronounced in PIϪ than they are in PIϩ patients (24) and might have contributed to the lower whole body protein synthesis and leucine balance observed in PIϪ compared with PIϩ patients.
In conclusion, the limited patient number of this crosssectional design and some heterogeneity of treatment combinations do not allow for a definitive conclusion on the effect of PIs on protein metabolism in HIV-infected patients. However, we believe that the results of the present study clearly show that whole body protein anabolism was improved in patients treated with PIs (i.e., increase in the nonoxidative leucine disposal and leucine balance), especially in response to an acute amino acid-glucose infusion. However, the absence of an associated increase in lean body mass suggests that it will be necessary to obtain more data to better analyze the effect of PI therapy on protein metabolism, not only in skeletal muscle but also in other potential targets. Whether a possible beneficial effect of PI therapy on lean body mass might occur during long-term, suitable nutritional support remains to be determined.
